Abstracts Archive - Page 2143 of 2425 - ACR Meeting Abstracts

Abstract Number: 1642 • 2013 ACR/ARHP Annual Meeting
CD25+CD39+ Regulatory T Cells Are Enriched At The Site Of Inflammation Of Patients With Rheumatoid Arthritis and Impaired In Suppressing IL-17A Secretion
Jessica Herrath¹, Karine Chemin², Inka Albrecht¹, Anca Catrina² and Vivianne Malmström³, ¹Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden, ²Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Regulatory T cells (Tregs) are important for the maintenance of self-tolerance and are implicated in the origin of autoimmunity. Despite enrichment of Tregs in…
Abstract Number: 1603 • 2013 ACR/ARHP Annual Meeting
Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus
Herbert Struemper¹, William Freimuth², Christi Kleoudis³, Thi-Sau Migone⁴, David Roth³ and William Stohl⁵, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Human Genome Sciences, Inc., Rockville, MD, ³GlaxoSmithKline, King of Prussia, PA, ⁴Igenica, Burlingame, CA, ⁵Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Belimumab treatment in autoantibody-positive systemic lupus erythematosus (SLE) patients for up to 76 weeks results in sustained reduction in several circulating B cell subsets,…
Abstract Number: 1604 • 2013 ACR/ARHP Annual Meeting
Effects Of Chronic Treatment With Blisibimod, An Inhibitor Of B Cell Activating Factor, On Renal and Inflammation Biomarkers In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Richard A. Furie¹, Matthew Thomas², Alvina Chu³, Renee S. Martin³, Colin Hislop³ and Morton A. Scheinberg⁴, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Health and Research Centre, Trivandrum, Kerala, India, ³Anthera Pharmaceuticals Inc, Hayward, CA, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod on renal and inflammation biomarkers in patients with SLE during the phase 2b clinical trial PEARL-SC (NCT01162681)…
Abstract Number: 1605 • 2013 ACR/ARHP Annual Meeting
Post-Marketing Experience With Belimumab In U.S. Lupus Centers: Data From The Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry
Jinoos Yazdany¹, Doruk Erkan², Jorge sanchez-Guerrero³, Bevra H. Hahn⁴, Alana B. Levine², Galina Marder⁵, W. Joseph McCune⁶ and Ellen M. Ginzler⁷, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Medicine, North Shore Long Island Health System, Great Neck, NY, ⁶Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁷Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Much of the published experience with belimumab in lupus patients has derived from clinical trials. We examined the non-sponsored experience with belimumab in routine…
Abstract Number: 1606 • 2013 ACR/ARHP Annual Meeting
Overview Of The Safety Of Epratuzumab In Systemic Lupus Erythematosus
Daniel J. Wallace¹, Josep Ordi-Ros², C. Michael Neuwelt³, Kenneth Kalunian⁴, Michelle A. Petri⁵, Slawomir Jeka⁶, Ronald F. van Vollenhoven⁷, Brian Kilgallen⁸, Sabine Bongardt⁹, Caroline Gordon¹⁰ and Vibeke Strand¹¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Internal Medicine, Vall De Hebron General Hospt, Barcelona, Spain, ³East Bay Rheumatology Research Institute, San Leandro, CA, ⁴UCSD School of Medicine, La Jolla, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶2nd University Hospital in Bydgoszcz Medical College of Nicolaus Copernicus University, Bydgoszcz, Poland, ⁷Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ¹¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The efficacy and safety of epratuzumab, a monoclonal antibody targeting CD22, has been evaluated in patients with moderate-to-severe systemic lupus erythematosus (SLE). A pooled…
Abstract Number: 1607 • 2013 ACR/ARHP Annual Meeting
Two Year Follow-Up On Biologics Use In 13 Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus
Ronald F. van Vollenhoven¹, Melinda Mild², Søren Jacobsen³, S. Bernatsky⁴, Daniel J. Wallace⁵, Sang-Cheol Bae⁶, Manuel Ramos-Casals⁷, Francisco J. García-Hernández⁸, R. Ramsey-Goldman⁹, Andrea Doria¹⁰, Marta Mosca¹¹, Michelle A. Petri¹², M Ayala-Gutiérrez¹³, J.G. Hanley¹⁴ and for The SLICC group¹⁵, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁷Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ⁸Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain, ⁹Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, ¹¹Rheumatology Unit, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹³Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Carlos Haya, Malaga, Spain, ¹⁴Division of Rheumatology, Halifax, NS, Canada, ¹⁵Department of Medicine, the Karolinska Institute, Stockholm, Sweden
Background/Purpose: Only one biologic agent has been approved for use in SLE, but some are used off-label in various settings. To obtain systematic information regarding…
Abstract Number: 1608 • 2013 ACR/ARHP Annual Meeting
A Phase I Single-Dose Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy Of AMG 811 (anti-IFN-gamma) In Subjects With Discoid Lupus Erythematosus
Victoria P. Werth¹, David Fiorentino², Stanley B. Cohen³, David Fivenson⁴, Chris Hansen⁵, Steve Zoog⁶, Greg Arnold⁷, Christine Wang⁸, Michael Boedigheimer⁶, Andrew Welcher⁶, James Chung⁶, Barbara Sullivan⁶ and David A. Martin⁹, ¹Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, ²Dermatology, Stanford University School of Medicine, Redwood City, CA, ³Metroplex Clinical Research Center, Dallas, TX, ⁴David Fivenson, MD, Dermatology, PLLC, Ann Arbor, MI, ⁵University of Utah School of Medicine, Salt Lake City, UT, ⁶Amgen, Thousand Oaks, CA, ⁷Medical Sciences, Amgen, Thousand Oaks, CA, ⁸Biostatistics, Amgen, Thousand Oaks, CA, ⁹Medical Sciences, Amgen, Seattle, WA
Background/Purpose: Discoid Lupus Erythematosus (DLE) is the most common form of chronic cutaneous LE (CCLE) and develops in up to a quarter of SLE patients.…
Abstract Number: 1609 • 2013 ACR/ARHP Annual Meeting
AMG 811 (anti-IFN-gamma) Treatment Leads To a Reduction In The Whole Blood IFN-Signature and Serum CXCL10 In Subjects With Systemic Lupus Erythematosus: Results Of Two Phase I Studies
David A. Martin¹, Andrew Welcher², Michael Boedigheimer², Zahir Amoura³, Alan Kivitz⁴, Jill P. Buyon⁵, Jorge Sanchez-Guerrero⁶, Juanita Romero-Diaz⁷, Alla Rudinskaya⁸, Kevin M. Latinis⁹, S Cohen¹⁰, Cynthia Aranow¹¹, Mike Damore², Winnie Sohn², Kit Chiu², Christine Wang¹², Naren Chirmule², Barbara Sullivan² and James Chung², ¹Medical Sciences, Amgen, Seattle, WA, ²Amgen, Thousand Oaks, CA, ³Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Danbury Hospital, Danbury, CT, ⁹Latinis Rheumatology, Leawood, KS, ¹⁰Metroplex Clinical Research Center, Dallas, TX, ¹¹The Feinstein Institute, Manhasset, NY, ¹²Biostatistics, Amgen, Thousand Oaks, CA
Background/Purpose: Interferon-gamma (IFN-g) is a major pro-inflammatory cytokine that modulates the function of several important populations of immune cells including B cells, T cells, and…
Abstract Number: 1610 • 2013 ACR/ARHP Annual Meeting
Lymphoablation Including B Cell Depletion and Autologous Hematopoietic Stem Cell Transplantation Leads To Long Remissions In Treatment-Resistant Systemic Lupus Erythematosus Patients
Sarfaraz A. Hasni¹, Gabor G. Illei², Nikolay P. Nikolov³, Francis Hakim⁴, Susan Leitman⁴, James E. Balow⁵, Howard A. Austin⁶, Juan Gea-Banacloche⁴, Unsong Oh⁷, Paulo Muraro⁸, Claude Sportes⁹, Peter E. Lipsky¹⁰, Ronald Gress⁹, Steve Pavletic⁹ and Amrie Grammer¹¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ³NIDCR, NIH, Bethesda, MD, ⁴NCI, NIH, Bethesda, MD, ⁵Clinical Director, NIDDK, National Institutes of Health, Bethesda, MD, ⁶Kidney Disease Section, NIDDK/NIH, Bethesda, MD, ⁷NINDS, NIH, Bethesda, MD, ⁸NINDS/NIH, Bethesda, MD, ⁹NCI/NIH, Bethesda, MD, ¹⁰NIAMS/NIH, Bethesda, MD, ¹¹AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Over the past two decades, approximately 200 patients with severe systemic lupus erythematosus(SLE) have received autologous hematopoietic stem cell transplants (autoHSCT). More than half…
Abstract Number: 1611 • 2013 ACR/ARHP Annual Meeting
Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients
Ronald F. van Vollenhoven¹, Melinda Mild², Andrea Doria³, T. Dörner⁴, Gianfranco Ferraccioli⁵, Frederic Houssiau⁶, T.W.J. Huizinga⁷, David A. Isenberg⁸, László Kovács⁹, Guillermo Ruiz-Irastorza¹⁰, Danilo Squatrito¹¹, Alexandre Voskuyl¹², Marta Mosca¹³, G D Sebastiani¹⁴, Murat Inanç¹⁵, Gabriella Szücs¹⁶, Søren Jacobsen¹⁷, A. Castro¹⁸ and for The IRBIS-EMA group¹⁹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁶Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁹Department of Rheumatology, University of Szeged, Szeged, Hungary, ¹⁰Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ¹¹Center for Autoimmune Diseases, Department of Internal Medicine, Careggi Hospital- Florence, Florence, Italy, ¹²Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹³Rheumatology Unit, University of Pisa, Pisa, Italy, ¹⁴Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, ¹⁵Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹⁶Department of Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, ¹⁷Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ¹⁸Hospital Universitari de Reus, Spain, Reus, Spain, ¹⁹ClinTRID, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Rituximab (Rituxan, Mabthera; RTX) has not been approved for use in SLE, but uncontrolled observations have suggested efficacy in some patients and the medication…
Abstract Number: 1612 • 2013 ACR/ARHP Annual Meeting
Rituximab For Treatment Of Refractory Auto-Immune Hepatitis
Chadi Rakieh¹, Edward M. Vital², Paul Emery³ and Michael Martin¹, ¹Rheumatology, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom, ²Section of Musculoskeletal Disease, Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom, ³Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, LTHT, Leeds, United Kingdom, Leeds, United Kingdom
Background/Purpose: Auto-immune hepatitis (AIH), also known as lupoid hepatitis, is a chronic progressive disease of unknown aetiology. First-line therapy consists of corticosteroids alone or in…
Abstract Number: 1613 • 2013 ACR/ARHP Annual Meeting
Anti-Malarial Drugs (hydroxychloroquine and quinacrine) Decrease The Production Of Interferon-Alfa Initiated By TLR-9 Agonist
Ou Jin¹, Xi Zhang¹, Qiuxia Li¹, Lingkai Fang¹, Hongyue Huang¹, Chengcheng Hou¹, Zetao Liao¹, Qiujing Wei¹, Zhiming Lin², Dongfang Lin¹ and Jieruo Gu³, ¹Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ²Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: Toll-like receptor 9 (TLR-9) plays an important role in initiating innate immunity. The recognition of self DNA fragments by TLR-9 may results in the…
Abstract Number: 1614 • 2013 ACR/ARHP Annual Meeting
Hydroxychloroquine Reverse The Elevation Of Interferon-Alfa Initiated By TLR-9 Agonist Which Irresponsive To Glucocorticoid
Ou Jin¹, Xi Zhang¹, Lingkai Fang¹, Qiuxia Li¹, Hongyue Huang¹, Zhiming Lin², Zetao Liao¹, Dongfang Lin¹, Chengcheng Hou¹ and Jieruo Gu³, ¹Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ²Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by chronic stimulation of the innate immune system by endogenous nucleic acids through toll-like receptors (TLRs) pathway, which…
Abstract Number: 1615 • 2013 ACR/ARHP Annual Meeting
Type I Interferons As a Serum Biomarker Of Subclinical Atherosclerosis In Pediatric Systemic Lupus Erythematosus Patients
Smriti Mohan¹, Julie Barsalou², Timothy J. Bradley³, Cameron Slorach³, Lawrence Ng⁴, Deborah M. Levy⁵, Earl D. Silverman² and Mariana J. Kaplan⁶, ¹Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁶Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder with a marked increase in cardiovascular (CV) morbidity and mortality due to premature atherosclerosis, distinct…
Abstract Number: 1616 • 2013 ACR/ARHP Annual Meeting
Interferon Regulatory Factors 3 and 5 As Key Elements Of The Interferon Signature On Plasmacytoid Dendritic Cells From Systemic Lupus Erythematosus Patients
Diana Gómez-Martín¹, Karina Santana-de Anda², Adriana Elizabeth Monsivais-Urenda³, Sandra Rajme-Lopez⁴, Luis Aparicio-Vera⁴, Jorge Alcocer-Varela¹ and Roberto González-Amaro³, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, ³Department of Immunology, Facultad de Medicina. UASLP, San Luis Potosí, Mexico, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico
Background/Purpose: Plasmacytoid dendritic cells (pDC) are considered the main source of type-I interferon (IFN-I). The interferon signature has been widely associated to systemic lupus erythematosus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].